Shangkun Zhang

Wuhan, 430078, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment.

Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment.

Journal: Journal of hematology & oncology

Published: March 05, 2026

EBV-associated lymphoproliferative disease post-CAR-T cell therapy.

EBV-associated lymphoproliferative disease post-CAR-T cell therapy.

Journal: Frontiers of medicine

Published: June 01, 2023

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma.

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma.

Journal: Experimental hematology & oncology

Published: August 15, 2022

Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel.

Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel.

Journal: Nature biomedical engineering

Published: March 23, 2022

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.

Journal: Frontiers in immunology

Published: February 20, 2022

T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.

T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.

Journal: Frontiers in immunology

Published: February 11, 2022

The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.

The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.

Journal: Scientific reports

Published: November 15, 2021

Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.

Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.

Journal: Signal transduction and targeted therapy

Published: October 05, 2021

CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.

CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.

Journal: Journal of hematology & oncology

Published: August 19, 2021

Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy.

Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy.

Journal: Blood cancer journal

Published: June 29, 2021

CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.

CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.

Journal: Transplantation and cellular therapy

Published: May 22, 2021

Long-term outcomes of relapsed/refractory double-hit lymphoma (r/r DHL) treated with CD19/22 CAR T-cell cocktail therapy.

Long-term outcomes of relapsed/refractory double-hit lymphoma (r/r DHL) treated with CD19/22 CAR T-cell cocktail therapy.

Journal: Clinical and translational medicine

Published: August 08, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026